healthcare
healthcare Articles
PhaseBio Pharmaceuticals announced early on Friday that it has initiated its midstage study evaluating a treatment for the novel coronavirus.
Published:
The number of COVID-19 cases continues to rise, which will only create more demand for coronavirus stocks. 24/7 Wall Street has picked out a few of the best and brightest that could still see a big...
Published:
Johnson & Johnson released better than expected quarterly results and guidance before the markets opened on Thursday.
Published:
Immutepjoins the ever-growing list of coronavirus stocks by announcing that it was granted a patent related to COVID-19 antibodies.
Published:
Moderna made another big step forward in the fight against COVID-19 after the company reported incredibly positive data from the early-stage trial of its coronavirus vaccine.
Published:
UnitedHealth Group released mixed second-quarter financial results and maintained its guidance before the markets opened on Wednesday.
Published:
IMV shares surged on Tuesday after the company provided an update on its vaccine candidate for COVID-19.
Published:
Blueprint Medicines announced early on Tuesday that it had entered into a global collaboration with pharmaceutical giant Roche in which it may receive up to $1.7 billion.
Published:
One of the most important aspects of reopening the economy during this pandemic is testing for COVID-19. Credit Suisse sees a couple of winners benefitting incredibly from this.
Published:
Pfizer and BioNTech have progressed in their COVID-19 vaccine effort, according to the FDA. Two of the companies’ four coronavirus vaccine candidates received Fast Track Designation.
Published:
The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
One big merger was announced Wednesday when Allstate offered to pay $4 billion in cash for insurer National General. A second merger between two medical device makers has also been rumored.
Published:
NanoViricides made another stride in the fight against COVID-19, and investors have to be happy about it.
Published:
Pfizer is among the current frontrunners for a COVID-19 vaccine, so why is its stock down 13% year to date? And why does one independent research firm say this stock could run much higher?
Published:
After Corvus Pharmaceuticals announced that it would initiate an early-stage immunotherapy study in patients with COVID-19, Wedush sees this stock running much higher.
Published: